GSK PLC Sponsored ADR (GSK)
(Real Time Quote from BATS)
$40.12 USD
+0.26 (0.65%)
Updated Jul 29, 2024 12:16 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Price, Consensus and EPS Surprise
GSK 40.12 +0.26(0.65%)
Will GSK be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GSK
Here's Why GSK (GSK) is a Strong Momentum Stock
Here's Why GSK (GSK) is a Strong Momentum Stock
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
Other News for GSK
Global company events calendar
UK earnings, trading statements calendar - next 7 days
GSK and Flagship Pioneering partner to discover novel medicines and vaccines
GSK, Flagship Pioneering announce collaboration
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings